Shaanxi Meibang Pharmaceutical Group Co Ltd Working Capital to Net Assets Ratio
Shaanxi Meibang Pharmaceutical Group Co Ltd working capital to net assets ratio. Shaanxi Meibang Pharmaceutical Group Co Ltd (605033) has a Working Capital to Net Assets ratio of 45.7% as of September 2025. Working capital of CN¥524.65 Million (current assets of CN¥1.06 Billion minus current liabilities of CN¥530.88 Million) is measured against net assets of CN¥1.15 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check tangible equity quality of Shaanxi Meibang Pharmaceutical Group Co to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Shaanxi Meibang Pharmaceutical Group Co Ltd (2017–2024)
Working capital to net assets ratio of Shaanxi Meibang Pharmaceutical Group Co Ltd from 2017 to 2024. This chart shows how Shaanxi Meibang Pharmaceutical Group Co Ltd's Working Capital to Net Assets ratio has evolved across 8 annual periods from 2017 to 2024. As of September 2025, the ratio stands at 45.7%, reflecting working capital of CN¥524.65 Million against net assets of CN¥1.15 Billion CNY. See how many days can Shaanxi Meibang Pharmaceutical Group Co fund operations to measure how many days the company can operate on defensive assets alone.
Shaanxi Meibang Pharmaceutical Group Co Ltd Working Capital to Net Assets Ratio by Year (2017–2024)
Shaanxi Meibang Pharmaceutical Group Co Ltd working capital to net assets ratio by year from 2017 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Shaanxi Meibang Pharmaceutical Group Co Ltd from 2017 to 2024, covering 8 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see 605033 total assets.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 42.7% | CN¥480.45 Million | CN¥1.12 Billion | CN¥1.10 Billion | CN¥616.26 Million | ▼ -12.1 pp |
| 2023 | 54.8% | CN¥610.89 Million | CN¥1.11 Billion | CN¥1.07 Billion | CN¥460.91 Million | ▼ -20.5 pp |
| 2022 | 75.4% | CN¥818.69 Million | CN¥1.09 Billion | CN¥1.19 Billion | CN¥369.72 Million | ▼ -2.8 pp |
| 2021 | 78.2% | CN¥755.71 Million | CN¥966.95 Million | CN¥1.19 Billion | CN¥437.07 Million | ▲ +12.4 pp |
| 2020 | 65.7% | CN¥295.43 Million | CN¥449.37 Million | CN¥606.16 Million | CN¥310.73 Million | ▼ -4.6 pp |
| 2019 | 70.4% | CN¥260.87 Million | CN¥370.63 Million | CN¥536.45 Million | CN¥275.58 Million | ▲ +2.9 pp |
| 2018 | 67.5% | CN¥186.52 Million | CN¥276.37 Million | CN¥478.37 Million | CN¥291.85 Million | ▲ +8.4 pp |
| 2017 | 59.1% | CN¥106.58 Million | CN¥180.43 Million | CN¥426.47 Million | CN¥319.90 Million | — |